MNMD vs. USNA, BTMD, CGC, ACB, CRON, CDXC, MDWD, CVAC, PRME, and SLN
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include USANA Health Sciences (USNA), biote (BTMD), Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), ChromaDex (CDXC), MediWound (MDWD), CureVac (CVAC), Prime Medicine (PRME), and Silence Therapeutics (SLN). These companies are all part of the "medical" sector.
Mind Medicine (MindMed) (NASDAQ:MNMD) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.
Mind Medicine (MindMed) presently has a consensus target price of $17.67, suggesting a potential upside of 94.78%. USANA Health Sciences has a consensus target price of $46.00, suggesting a potential downside of 4.09%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than USANA Health Sciences.
Mind Medicine (MindMed) has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
In the previous week, Mind Medicine (MindMed) had 13 more articles in the media than USANA Health Sciences. MarketBeat recorded 22 mentions for Mind Medicine (MindMed) and 9 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 0.96 beat Mind Medicine (MindMed)'s score of 0.48 indicating that USANA Health Sciences is being referred to more favorably in the news media.
USANA Health Sciences has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 2.1% of Mind Medicine (MindMed) shares are owned by insiders. Comparatively, 0.3% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
USANA Health Sciences has a net margin of 6.88% compared to Mind Medicine (MindMed)'s net margin of 0.00%. USANA Health Sciences' return on equity of 12.80% beat Mind Medicine (MindMed)'s return on equity.
USANA Health Sciences received 359 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 90.00% of users gave Mind Medicine (MindMed) an outperform vote while only 60.68% of users gave USANA Health Sciences an outperform vote.
Summary
USANA Health Sciences beats Mind Medicine (MindMed) on 10 of the 17 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
